Roche silently whisks away its lead $1.7B Seragon drug in a Q1 footnote
Close to three years ago Roche’s Genentech team came in and bought out Seragon from Rich Heyman for $725 million in cash and another billion dollars in milestones, heralding the potential for selective estrogen receptor degraders to “one day redefine the standard of care for hormone receptor-positive breast cancer.”
Today, the pharma giant quietly carried the lead drug from that deal out to the curb, noting in a footnote on program terminations that it was removing the drug GDC-0810 (ARN-810, RG6046) from Phase II.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
